Viking's Weight Loss Drug VK2735 Shows Promising 5.3% Weight Loss in Phase 1 Trial
- VK2735 showed up to 5.3% weight loss from baseline and up to 3.3% placebo-adjusted weight loss in 28-day Phase 1 trial
- VK2735 was safe and well-tolerated with minimal GI side effects
- 57% of VK2735 subjects achieved ≥5% weight loss versus 0% on placebo
- Viking plans to initiate Phase 2 trial of oral VK2735 in obesity in 2H 2024
- Longer treatment duration may lead to further weight loss
